Profile
| Metric | Value |
|---|---|
| Full Name | Bio-Rad Laboratories, Inc. |
| Ticker | NYSE: BIO |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Medical Devices |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | bio-rad.com |
| Employees | 7,700 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $305.27 | |
| Price, 1D Change | +0.75% | |
| Market Cap | $8B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.04 | |
| Revenue | $3B | |
| Revenue, 1Y Change | -3.92% | |
| EPS | -$65.36 | |
| EPS, 1Y Change | -199.57% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 2:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$65.36 | |
| EPS Estimate | $9.95 | |
| EPS Est. Change | +115.23% | |
| Revenue | $2.57B | |
| Revenue Estimate | $2.58B | |
| Revenue Est. Change | +0.48% | |
| Current Price | $305.27 | |
| Price Target | - | $340.00 |
| Price Tgt. Change | - | +11.38% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $11.51 | -$21.82 | -289.57% | |
| $10.06 | -$65.36 | -749.63% | |
| $9.95 | N/A | +115.23% | |
| $10.15 | N/A | +115.53% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.68B | $2.67B | -0.15% | |
| $2.58B | $2.57B | -0.56% | |
| $2.58B | N/A | +0.48% | |
| $2.64B | N/A | +2.73% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | -6.40% | |
| Price, 3Y | -27.40% | |
| Market Cap, 1Y | -9.87% | |
| Market Cap, 3Y | -33.83% | |
| Revenue, 1Y | -3.92% | |
| Revenue, 3Y | -12.18% | |
| EPS, 1Y | -199.57% | |
| EPS, 3Y | -146.41% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $305.27 | |
| SMA 200 | $272.98 | |
| SMA 200 vs Price | -10.58% | |
| SMA 50 | $313.62 | |
| SMA 50 vs Price | +2.74% | |
| Beta | 1.04 | |
| ATR | $7.70 | |
| 14-Day RSI | 46.95 | |
| 10-Day Volatility | 11.31% | |
| 1-Year Volatility | 43.29% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $2.57B | |
| EPS | -$65.36 | |
| Gross Profit | $1.38B | |
| Gross Margin | 53.73% | |
| Operating Profit | $311.00M | |
| Operating Margin | -34.16% | |
| Net Income | -$1.84B | |
| Net Margin | -71.86% | |
| EBITDA | $503.80M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.21 | |
| Current Ratio | 6.48 | |
| Quick Ratio | 4.85 | |
| - | ||
| F-Score | 4 | |
| Altman Z-Score | 3.59 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 3.22 | |
| PB Ratio | 1.22 | |
| EV/EBITDA | 16.76 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $6.57B | |
| Cash & Equivalents | $1.67B | |
| Total Assets | $9.36B | |
| Current Assets | $3.03B | |
| Total Liabilities | $2.79B | |
| Current Liabilities | $467.80M | |
| Total Debt | $1.38B | |
| Short Term Debt | $43.30M | |
| Accounts Payable | $122.30M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $4.41B | |
| Operating Expenses | $1.07B | |
| Cost Of Goods Sold | $1.19B | |
| SG&A | $0.00 | |
| D&A | $192.80M | |
| Interest Expense | $0.00 | |
| Income Tax | -$498.30M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $454.60M | |
| CFI | -$160.20M | |
| CFF | -$218.20M | |
| Capex | $165.60M | |
| Free Cash Flow | $289.00M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wells Fargo | → | |
| Citigroup | → | |
| Wells Fargo | → | |
| RBC Capital | → | |
| Wells Fargo | → | |
| UBS | → | |
| RBC Capital | → | |
| Citigroup | → | |
| Wells Fargo | → | |
| Wells Fargo | → |
Analyst sentiment
Institutional ownership
Screeners with BIO
Data Sources & References
- BIO Official Website www.bio-rad.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/12208/000001220825000077/0000012208-25-000077-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/12208/000001220825000007/0000012208-25-000007-index.htm
- BIO Profile on Yahoo Finance finance.yahoo.com/quote/BIO
- BIO Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/bio
FAQ
What is the ticker symbol for Bio-Rad Laboratories, Inc.?
The ticker symbol for Bio-Rad Laboratories, Inc. is NYSE:BIO
Does Bio-Rad Laboratories, Inc. pay dividends?
No, Bio-Rad Laboratories, Inc. does not pay dividends
What sector is Bio-Rad Laboratories, Inc. in?
Bio-Rad Laboratories, Inc. is in the Healthcare sector
What industry is Bio-Rad Laboratories, Inc. in?
Bio-Rad Laboratories, Inc. is in the Medical Devices industry
What country is Bio-Rad Laboratories, Inc. based in?
Bio-Rad Laboratories, Inc. is headquartered in United States
When did Bio-Rad Laboratories, Inc. go public?
Bio-Rad Laboratories, Inc. initial public offering (IPO) was on February 27, 1980
Is Bio-Rad Laboratories, Inc. in the S&P 500?
No, Bio-Rad Laboratories, Inc. is not included in the S&P 500 index
Is Bio-Rad Laboratories, Inc. in the NASDAQ 100?
No, Bio-Rad Laboratories, Inc. is not included in the NASDAQ 100 index
Is Bio-Rad Laboratories, Inc. in the Dow Jones?
No, Bio-Rad Laboratories, Inc. is not included in the Dow Jones index
When was Bio-Rad Laboratories, Inc. last earnings report?
Bio-Rad Laboratories, Inc.'s most recent earnings report was on October 29, 2025
When does Bio-Rad Laboratories, Inc. report earnings?
The next expected earnings date for Bio-Rad Laboratories, Inc. is February 12, 2026